Member Info for Candid

Further good news and the newly identified potential uses just increases the scope of the commercial opportunity

This news about a competitor’s POC solution is where GDR will be very soon.
https://www.bbc.co.uk/news/uk-england-tyne-56366417
Expected launch of the Genedrive POC solution is in March according to previous updates. The GDR solution is based on their flagship handheld device that is already proven in other POC testing applications (HCV testing kit, US DoD etc.) and it already has WHO Pre-Qualify status for the HCV test solution.
The sooner GDR launches the POC solution the better as the commercial opportunity is very much present and growing.

Deal activity starting to emerge in North Sea M&A is definitely a good sign as these larger deals (announced in recent days by Cairn, Catcher, Kracken, also Neo Petroleum etc) might unlock further deals due to project portfolio divestments.
I still think the most likely scenario is a deal in the Norwegian continental shelf of the North Sea, at an advanced stage, as the ex-Faroe management have the best knowledge, experience and contacts there. Equally it could be wherever the best opportunity emerges.

Interesting to see that US laboratories still have ongoing testing supply chain issues, including test kits and reagents.

https://www.aacc.org/cln/articles/2021/march/aacc-warns-of-continuing-supply-chain-problems

Not surprisingly really as there are only 10m shares in issue. So this ‘small’ purchase of 25,000 shares is equivalent of 0.25% of the company. Three more similar purchases and you’re suddenly holding 1% of the company.

FinnCap update on GDR this morning and although they have no price target yet due to arious models of sales not available yet they reiterate that the shareprice has potential for significant upside
Also worth noting that new covid cases are now on the rise again in USA, Italy, Germany, France, Brazil and also other parts of Europe. Testing demand is due to increase.

DEST has ambitions to be a world leading infection prevention company. That’s quite a statement for a £60m market cap company.
Very significant month ahead for DEST for one of it’s main assets XF-73. Lets not forget what’s at stake here, the following is from the RNS update in Feb:

“We recently completed enrollment in our Phase 2b clinical trial testing XF-73 nasal gel as a novel product preventing the incidence of post-surgical infections such as MRSA. We are now looking forward to announcing the full results of this study towards the end of March 2021 and planning the Phase 3 clinical programme. There is also a significant commercial opportunity for XF-73 in the hospital setting which we estimate could generate peak annual product sales of $1 billion in the US alone."
Partnering will come later this year including US, China and RoW

The 2nd main asset NTCD-M3 (difficile) also has huge potential and will move into phase 3.
The 3rd early-stage asset (SporeGen) for covid prevention is in development.

Just been thinking about the live investor presentation that is planned to accompany the interim results, the BOD haven’t done this for any previous results and I can only conclude that there will be a highly encouraging and bullish outlook to communicate, otherwise they would not voluntarily opt to hold this live investor presentation with Q&A.

Just noticed today’s announcement from SourceBio and this expansion move clearly means the PCR testing demand in US is growing..
"This further investment in our San Diego facility increases our overall capacity to increase COVID-19 qPCR testing services by up to an additional 5,000 samples per day and means we can address the clear market demand for COVID-19 testing in the US."

https://www.lse.co.uk/rns/SBI/us-expansion-of-covid-19-testing-services-970m1caqlq31g1g.html

There is a growing need for rapid POC solutions in the UK, US and worldwide.
A perfect time for GDR to launch it’s Genedrive® SARS-CoV-2 Kit for Point of Care. The anticipated product launch date is March 2021 (as previously outlined by the company).
Remember that the Genedrive device is a tried and tested portable unit that has already been in use for various diagnostic tests, including HCV, where it has already received WHO PQ status.
Now is the time for the launch of the POC solution, the sooner the better.

I believe it is relevant to get FDA EUA approval to commence sales in a large scale in US. So this should be a major catalyst.
“the FDA has stated that it does not object to a commercial manufacturer's development and distribution of SARS-CoV-2 test kits for specimen testing for a reasonable period of time, where the test has been validated and while the manufacturer has made an Emergency Use Authorization request”

Emergency Use Authorisation with the US FDA and Emergency Use Assessment and Listing with the WHO.
With both of these applied for in June 2020, surely this must be imminent now? I know FDA and WHO are overwhelmed by various other applications, including vaccinations, but 8 months is a long time to get Emergency Use Approval, especially with Beckman Coulter and Cytiva involved with this.
Once approval from FDA and/or WHO are obtained, I expect GDR to jump up strongly and not look back

I think this announcement is due sooner rather than later, they are due to launch it in the US market and it would not surprise me to see a tie-up with a big US pharma partner to commercialise it.
“We enter 2021 with an expanded strategic focus, team, and infrastructure to drive near-term commercialization of the EpiSwitch ™ technology, via multiple commercial pathways, beginning with our COVID-19 severity test” (from the annual results a few weeks ago)

Any thoughts as to when the results of this trial will be announced.
I think it could be soon.
Patient numbers fully enrolled for this trial was announced on 20th Jan:
“recruitment of 120 COVID-19 patients into its Phase II trial evaluating inhaled formulation of interferon-beta-1a (SNG001) conducted in the home setting has now been completed. Results from the trial are expected in Q2 2021”
Going by the previous data readout (magic Monday) on 20th July 2020, the announced full enrolment of patients was around 7 weeks prior to that.
The data readout might come sooner than expected as they already have the protocol in place for data analysis from last year.
They could of course hold off until the data from Active 2 trial is also available and announce both together. Thoughts?

It doesn’t work like that with investment vehicles, you won’t see any effects of dilution. YCA will use the proceeds of the placing to purchase additional U308 and this will go straight to the NAV which underpins the share price.
I can see the uranium market tightening as more supply is taken off the table. The spot price is bound to make a strong upward recovery as utilities, traders, funds start meaningful buying.

Are we expecting a rise on the open tomorrow?

A mere 4% discount to today’s market price, seems hardly worth the effort for retail investors. What’s the incentive?

Yep, not a lot of shares is issue.
10,000 shares for 91.9p available to buy right now

Liquidity here is very small, only 10m shares in issue and at least 70% of these are tightly held by funds and insiders. Hence not easy to buy or sell.
I think we’ll see a deal far in excess of current market cap, so we await to see how it’s structured, prob a mix of debt and new equity. The real draw here is the ex-management of Faroe Petroleum, who are experienced deal makers. They are in for free at the moment.

This is encouraging for the sector but lets not forget that BA, Iberia and Aer Lingus are not purely leisure airlines. They are not reliant on people making holiday bookings, their bread and butter has always been business travel.
Many in the travel industry are predicting a robust recovery in leisure travel once borders can properly reopen as there is a dash for overseas trips, business travel, which can generate as much as 75 per cent of airlines’ revenue on some international flights has fundamentally changed and will not recover anytime soon.